nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—ABCB1—Mitomycin—stomach cancer	0.0736	0.168	CbGbCtD
Sirolimus—SLCO1B1—Irinotecan—stomach cancer	0.0659	0.151	CbGbCtD
Sirolimus—CYP3A7—Irinotecan—stomach cancer	0.0387	0.0884	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Irinotecan—stomach cancer	0.0387	0.0884	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—stomach cancer	0.0349	0.0797	CbGbCtD
Sirolimus—CYP3A5—Irinotecan—stomach cancer	0.029	0.0663	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Docetaxel—stomach cancer	0.0284	0.0648	CbGbCtD
Sirolimus—CYP3A7—Docetaxel—stomach cancer	0.0284	0.0648	CbGbCtD
Sirolimus—CYP3A5—Docetaxel—stomach cancer	0.0213	0.0486	CbGbCtD
Sirolimus—ABCB1—Irinotecan—stomach cancer	0.0189	0.0432	CbGbCtD
Sirolimus—ABCB1—Docetaxel—stomach cancer	0.0138	0.0316	CbGbCtD
Sirolimus—CYP3A4—Irinotecan—stomach cancer	0.0113	0.0259	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—stomach cancer	0.0103	0.0236	CbGbCtD
Sirolimus—ABCB1—Methotrexate—stomach cancer	0.01	0.0228	CbGbCtD
Sirolimus—CYP3A4—Docetaxel—stomach cancer	0.00829	0.0189	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—stomach cancer	0.00618	0.0141	CbGbCtD
Sirolimus—EIF4E—hematopoietic system—stomach cancer	0.0054	0.0666	CbGeAlD
Sirolimus—EIF4E—pancreas—stomach cancer	0.0044	0.0542	CbGeAlD
Sirolimus—MTOR—blood vessel—stomach cancer	0.00393	0.0484	CbGeAlD
Sirolimus—EIF4E—lymphoid tissue—stomach cancer	0.0038	0.0469	CbGeAlD
Sirolimus—EIF4E—digestive system—stomach cancer	0.00376	0.0463	CbGeAlD
Sirolimus—EIF4E—endocrine gland—stomach cancer	0.0031	0.0383	CbGeAlD
Sirolimus—FGF2—smooth muscle tissue—stomach cancer	0.0029	0.0358	CbGeAlD
Sirolimus—EIF4E—liver—stomach cancer	0.0028	0.0345	CbGeAlD
Sirolimus—MTOR—hematopoietic system—stomach cancer	0.00209	0.0258	CbGeAlD
Sirolimus—MTOR—epithelium—stomach cancer	0.00191	0.0236	CbGeAlD
Sirolimus—FKBP1A—hematopoietic system—stomach cancer	0.00188	0.0232	CbGeAlD
Sirolimus—MTOR—smooth muscle tissue—stomach cancer	0.00184	0.0227	CbGeAlD
Sirolimus—FKBP1A—epithelium—stomach cancer	0.00172	0.0212	CbGeAlD
Sirolimus—MTOR—pancreas—stomach cancer	0.0017	0.021	CbGeAlD
Sirolimus—FKBP1A—smooth muscle tissue—stomach cancer	0.00166	0.0204	CbGeAlD
Sirolimus—SLC47A1—hematopoietic system—stomach cancer	0.00162	0.0199	CbGeAlD
Sirolimus—SLCO1B1—hematopoietic system—stomach cancer	0.0016	0.0197	CbGeAlD
Sirolimus—FKBP1A—pancreas—stomach cancer	0.00153	0.0189	CbGeAlD
Sirolimus—MTOR—lymphoid tissue—stomach cancer	0.00147	0.0181	CbGeAlD
Sirolimus—MTOR—digestive system—stomach cancer	0.00145	0.0179	CbGeAlD
Sirolimus—MTOR—bone marrow—stomach cancer	0.00134	0.0165	CbGeAlD
Sirolimus—CYP3A7—endocrine gland—stomach cancer	0.00134	0.0165	CbGeAlD
Sirolimus—FKBP1A—lymphoid tissue—stomach cancer	0.00132	0.0163	CbGeAlD
Sirolimus—FGF2—lymph node—stomach cancer	0.00131	0.0161	CbGeAlD
Sirolimus—FKBP1A—digestive system—stomach cancer	0.00131	0.0161	CbGeAlD
Sirolimus—FKBP1A—bone marrow—stomach cancer	0.00121	0.0149	CbGeAlD
Sirolimus—CYP3A7—liver—stomach cancer	0.00121	0.0149	CbGeAlD
Sirolimus—MTOR—endocrine gland—stomach cancer	0.0012	0.0148	CbGeAlD
Sirolimus—SLC47A1—digestive system—stomach cancer	0.00112	0.0139	CbGeAlD
Sirolimus—SLCO1B1—digestive system—stomach cancer	0.00111	0.0137	CbGeAlD
Sirolimus—MTOR—liver—stomach cancer	0.00108	0.0134	CbGeAlD
Sirolimus—FKBP1A—endocrine gland—stomach cancer	0.00108	0.0133	CbGeAlD
Sirolimus—CYP3A7-CYP3A51P—liver—stomach cancer	0.00102	0.0126	CbGeAlD
Sirolimus—FKBP1A—liver—stomach cancer	0.000974	0.012	CbGeAlD
Sirolimus—SLC47A1—endocrine gland—stomach cancer	0.000928	0.0114	CbGeAlD
Sirolimus—SLCO1B1—endocrine gland—stomach cancer	0.000917	0.0113	CbGeAlD
Sirolimus—SLC47A1—liver—stomach cancer	0.000837	0.0103	CbGeAlD
Sirolimus—MTOR—lymph node—stomach cancer	0.00083	0.0102	CbGeAlD
Sirolimus—SLCO1B1—liver—stomach cancer	0.000826	0.0102	CbGeAlD
Sirolimus—CYP3A5—hematopoietic system—stomach cancer	0.000819	0.0101	CbGeAlD
Sirolimus—ABCB1—blood vessel—stomach cancer	0.000817	0.0101	CbGeAlD
Sirolimus—FKBP1A—lymph node—stomach cancer	0.000747	0.00921	CbGeAlD
Sirolimus—CYP3A5—pancreas—stomach cancer	0.000667	0.00822	CbGeAlD
Sirolimus—SLC47A1—lymph node—stomach cancer	0.000642	0.00791	CbGeAlD
Sirolimus—CYP3A4—hematopoietic system—stomach cancer	0.000614	0.00757	CbGeAlD
Sirolimus—CYP3A5—digestive system—stomach cancer	0.000569	0.00702	CbGeAlD
Sirolimus—CYP3A5—endocrine gland—stomach cancer	0.00047	0.0058	CbGeAlD
Sirolimus—ABCB1—hematopoietic system—stomach cancer	0.000435	0.00536	CbGeAlD
Sirolimus—CYP3A4—digestive system—stomach cancer	0.000427	0.00527	CbGeAlD
Sirolimus—CYP3A5—liver—stomach cancer	0.000424	0.00523	CbGeAlD
Sirolimus—ABCB1—epithelium—stomach cancer	0.000398	0.0049	CbGeAlD
Sirolimus—ABCB1—pancreas—stomach cancer	0.000354	0.00437	CbGeAlD
Sirolimus—CYP3A4—endocrine gland—stomach cancer	0.000353	0.00435	CbGeAlD
Sirolimus—CYP3A4—liver—stomach cancer	0.000318	0.00392	CbGeAlD
Sirolimus—ABCB1—lymphoid tissue—stomach cancer	0.000306	0.00377	CbGeAlD
Sirolimus—ABCB1—digestive system—stomach cancer	0.000302	0.00373	CbGeAlD
Sirolimus—ABCB1—bone marrow—stomach cancer	0.000279	0.00344	CbGeAlD
Sirolimus—ABCB1—endocrine gland—stomach cancer	0.00025	0.00308	CbGeAlD
Sirolimus—ABCB1—liver—stomach cancer	0.000225	0.00278	CbGeAlD
Sirolimus—ABCB1—lymph node—stomach cancer	0.000173	0.00213	CbGeAlD
Sirolimus—Hepatobiliary disease—Doxorubicin—stomach cancer	9.11e-05	0.000372	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—stomach cancer	9.09e-05	0.000371	CcSEcCtD
Sirolimus—Anorexia—Capecitabine—stomach cancer	9.09e-05	0.000371	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—stomach cancer	9.06e-05	0.00037	CcSEcCtD
Sirolimus—Vomiting—Irinotecan—stomach cancer	9.06e-05	0.00037	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—stomach cancer	9.04e-05	0.000369	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—stomach cancer	9.02e-05	0.000369	CcSEcCtD
Sirolimus—Dizziness—Fluorouracil—stomach cancer	9.02e-05	0.000369	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—stomach cancer	9.01e-05	0.000368	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—stomach cancer	9e-05	0.000368	CcSEcCtD
Sirolimus—Rash—Irinotecan—stomach cancer	8.98e-05	0.000367	CcSEcCtD
Sirolimus—Dermatitis—Irinotecan—stomach cancer	8.97e-05	0.000367	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Docetaxel—stomach cancer	8.97e-05	0.000367	CcSEcCtD
Sirolimus—Chills—Methotrexate—stomach cancer	8.96e-05	0.000366	CcSEcCtD
Sirolimus—Headache—Irinotecan—stomach cancer	8.92e-05	0.000365	CcSEcCtD
Sirolimus—Hypotension—Capecitabine—stomach cancer	8.91e-05	0.000364	CcSEcCtD
Sirolimus—Insomnia—Docetaxel—stomach cancer	8.9e-05	0.000364	CcSEcCtD
Sirolimus—Paraesthesia—Docetaxel—stomach cancer	8.84e-05	0.000361	CcSEcCtD
Sirolimus—Dyspnoea—Docetaxel—stomach cancer	8.78e-05	0.000359	CcSEcCtD
Sirolimus—Somnolence—Docetaxel—stomach cancer	8.75e-05	0.000358	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—stomach cancer	8.72e-05	0.000356	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—stomach cancer	8.69e-05	0.000355	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—stomach cancer	8.69e-05	0.000355	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Capecitabine—stomach cancer	8.68e-05	0.000355	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—stomach cancer	8.67e-05	0.000354	CcSEcCtD
Sirolimus—Vomiting—Fluorouracil—stomach cancer	8.67e-05	0.000354	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—stomach cancer	8.67e-05	0.000354	CcSEcCtD
Sirolimus—Dyspepsia—Docetaxel—stomach cancer	8.67e-05	0.000354	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—stomach cancer	8.65e-05	0.000353	CcSEcCtD
Sirolimus—Insomnia—Capecitabine—stomach cancer	8.62e-05	0.000352	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—stomach cancer	8.61e-05	0.000352	CcSEcCtD
Sirolimus—Rash—Fluorouracil—stomach cancer	8.6e-05	0.000351	CcSEcCtD
Sirolimus—Dermatitis—Fluorouracil—stomach cancer	8.59e-05	0.000351	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—stomach cancer	8.58e-05	0.000351	CcSEcCtD
Sirolimus—Paraesthesia—Capecitabine—stomach cancer	8.56e-05	0.00035	CcSEcCtD
Sirolimus—Decreased appetite—Docetaxel—stomach cancer	8.56e-05	0.00035	CcSEcCtD
Sirolimus—Headache—Fluorouracil—stomach cancer	8.55e-05	0.000349	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—stomach cancer	8.54e-05	0.000349	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—stomach cancer	8.52e-05	0.000348	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Docetaxel—stomach cancer	8.5e-05	0.000347	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—stomach cancer	8.5e-05	0.000347	CcSEcCtD
Sirolimus—Dyspnoea—Capecitabine—stomach cancer	8.5e-05	0.000347	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—stomach cancer	8.48e-05	0.000347	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—stomach cancer	8.48e-05	0.000346	CcSEcCtD
Sirolimus—Nausea—Irinotecan—stomach cancer	8.46e-05	0.000346	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—stomach cancer	8.44e-05	0.000345	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—stomach cancer	8.42e-05	0.000344	CcSEcCtD
Sirolimus—Constipation—Docetaxel—stomach cancer	8.42e-05	0.000344	CcSEcCtD
Sirolimus—Pain—Docetaxel—stomach cancer	8.42e-05	0.000344	CcSEcCtD
Sirolimus—Back pain—Methotrexate—stomach cancer	8.41e-05	0.000344	CcSEcCtD
Sirolimus—Dyspepsia—Capecitabine—stomach cancer	8.39e-05	0.000343	CcSEcCtD
Sirolimus—Chills—Epirubicin—stomach cancer	8.39e-05	0.000343	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—stomach cancer	8.33e-05	0.000341	CcSEcCtD
Sirolimus—Decreased appetite—Capecitabine—stomach cancer	8.29e-05	0.000339	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Capecitabine—stomach cancer	8.23e-05	0.000336	CcSEcCtD
Sirolimus—Pain—Capecitabine—stomach cancer	8.15e-05	0.000333	CcSEcCtD
Sirolimus—Constipation—Capecitabine—stomach cancer	8.15e-05	0.000333	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—stomach cancer	8.14e-05	0.000332	CcSEcCtD
Sirolimus—Feeling abnormal—Docetaxel—stomach cancer	8.11e-05	0.000332	CcSEcCtD
Sirolimus—Nausea—Fluorouracil—stomach cancer	8.1e-05	0.000331	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—stomach cancer	8.07e-05	0.00033	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—stomach cancer	8.06e-05	0.000329	CcSEcCtD
Sirolimus—Gastrointestinal pain—Docetaxel—stomach cancer	8.05e-05	0.000329	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—stomach cancer	8.04e-05	0.000328	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—stomach cancer	8.03e-05	0.000328	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—stomach cancer	8.02e-05	0.000328	CcSEcCtD
Sirolimus—Tension—Epirubicin—stomach cancer	7.98e-05	0.000326	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—stomach cancer	7.9e-05	0.000323	CcSEcCtD
Sirolimus—Back pain—Epirubicin—stomach cancer	7.87e-05	0.000322	CcSEcCtD
Sirolimus—Feeling abnormal—Capecitabine—stomach cancer	7.86e-05	0.000321	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—stomach cancer	7.85e-05	0.000321	CcSEcCtD
Sirolimus—Malaise—Methotrexate—stomach cancer	7.84e-05	0.00032	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—stomach cancer	7.82e-05	0.00032	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—stomach cancer	7.81e-05	0.000319	CcSEcCtD
Sirolimus—Gastrointestinal pain—Capecitabine—stomach cancer	7.79e-05	0.000318	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—stomach cancer	7.79e-05	0.000318	CcSEcCtD
Sirolimus—Abdominal pain—Docetaxel—stomach cancer	7.78e-05	0.000318	CcSEcCtD
Sirolimus—Body temperature increased—Docetaxel—stomach cancer	7.78e-05	0.000318	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—stomach cancer	7.78e-05	0.000318	CcSEcCtD
Sirolimus—Chills—Doxorubicin—stomach cancer	7.76e-05	0.000317	CcSEcCtD
Sirolimus—Cough—Methotrexate—stomach cancer	7.59e-05	0.00031	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—stomach cancer	7.55e-05	0.000308	CcSEcCtD
Sirolimus—Abdominal pain—Capecitabine—stomach cancer	7.54e-05	0.000308	CcSEcCtD
Sirolimus—Body temperature increased—Capecitabine—stomach cancer	7.54e-05	0.000308	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—stomach cancer	7.53e-05	0.000308	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—stomach cancer	7.52e-05	0.000307	CcSEcCtD
Sirolimus—Agitation—Epirubicin—stomach cancer	7.48e-05	0.000306	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—stomach cancer	7.42e-05	0.000303	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—stomach cancer	7.4e-05	0.000302	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—stomach cancer	7.4e-05	0.000302	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—stomach cancer	7.4e-05	0.000302	CcSEcCtD
Sirolimus—Tension—Doxorubicin—stomach cancer	7.39e-05	0.000302	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	7.35e-05	0.0003	CcSEcCtD
Sirolimus—Malaise—Epirubicin—stomach cancer	7.34e-05	0.0003	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—stomach cancer	7.31e-05	0.000299	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—stomach cancer	7.31e-05	0.000299	CcSEcCtD
Sirolimus—Syncope—Epirubicin—stomach cancer	7.3e-05	0.000298	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—stomach cancer	7.28e-05	0.000298	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—stomach cancer	7.28e-05	0.000298	CcSEcCtD
Sirolimus—Hypersensitivity—Docetaxel—stomach cancer	7.25e-05	0.000296	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—stomach cancer	7.24e-05	0.000296	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—stomach cancer	7.19e-05	0.000294	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—stomach cancer	7.16e-05	0.000292	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—stomach cancer	7.15e-05	0.000292	CcSEcCtD
Sirolimus—Cough—Epirubicin—stomach cancer	7.1e-05	0.00029	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—stomach cancer	7.1e-05	0.00029	CcSEcCtD
Sirolimus—Asthenia—Docetaxel—stomach cancer	7.06e-05	0.000289	CcSEcCtD
Sirolimus—Infection—Methotrexate—stomach cancer	7.05e-05	0.000288	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—stomach cancer	7.03e-05	0.000287	CcSEcCtD
Sirolimus—Hypersensitivity—Capecitabine—stomach cancer	7.02e-05	0.000287	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—stomach cancer	6.99e-05	0.000285	CcSEcCtD
Sirolimus—Pruritus—Docetaxel—stomach cancer	6.97e-05	0.000285	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—stomach cancer	6.96e-05	0.000284	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—stomach cancer	6.96e-05	0.000284	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—stomach cancer	6.95e-05	0.000284	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—stomach cancer	6.93e-05	0.000283	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—stomach cancer	6.93e-05	0.000283	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—stomach cancer	6.93e-05	0.000283	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—stomach cancer	6.92e-05	0.000283	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—stomach cancer	6.9e-05	0.000282	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—stomach cancer	6.89e-05	0.000282	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	6.88e-05	0.000281	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—stomach cancer	6.86e-05	0.00028	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—stomach cancer	6.84e-05	0.00028	CcSEcCtD
Sirolimus—Asthenia—Capecitabine—stomach cancer	6.84e-05	0.000279	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—stomach cancer	6.79e-05	0.000277	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—stomach cancer	6.76e-05	0.000276	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—stomach cancer	6.75e-05	0.000276	CcSEcCtD
Sirolimus—Pruritus—Capecitabine—stomach cancer	6.74e-05	0.000276	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—stomach cancer	6.74e-05	0.000275	CcSEcCtD
Sirolimus—Diarrhoea—Docetaxel—stomach cancer	6.74e-05	0.000275	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—stomach cancer	6.7e-05	0.000274	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—stomach cancer	6.65e-05	0.000272	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—stomach cancer	6.64e-05	0.000271	CcSEcCtD
Sirolimus—Oedema—Epirubicin—stomach cancer	6.64e-05	0.000271	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—stomach cancer	6.63e-05	0.000271	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—stomach cancer	6.62e-05	0.00027	CcSEcCtD
Sirolimus—Infection—Epirubicin—stomach cancer	6.6e-05	0.00027	CcSEcCtD
Sirolimus—Cough—Doxorubicin—stomach cancer	6.57e-05	0.000268	CcSEcCtD
Sirolimus—Shock—Epirubicin—stomach cancer	6.53e-05	0.000267	CcSEcCtD
Sirolimus—Diarrhoea—Capecitabine—stomach cancer	6.52e-05	0.000266	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—stomach cancer	6.51e-05	0.000266	CcSEcCtD
Sirolimus—Dizziness—Docetaxel—stomach cancer	6.51e-05	0.000266	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—stomach cancer	6.5e-05	0.000266	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—stomach cancer	6.5e-05	0.000266	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—stomach cancer	6.48e-05	0.000265	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—stomach cancer	6.47e-05	0.000264	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—stomach cancer	6.45e-05	0.000264	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—stomach cancer	6.42e-05	0.000262	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—stomach cancer	6.42e-05	0.000262	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—stomach cancer	6.41e-05	0.000262	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—stomach cancer	6.41e-05	0.000262	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—stomach cancer	6.41e-05	0.000262	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—stomach cancer	6.39e-05	0.000261	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—stomach cancer	6.37e-05	0.00026	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	6.37e-05	0.00026	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—stomach cancer	6.33e-05	0.000259	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—stomach cancer	6.33e-05	0.000259	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—stomach cancer	6.33e-05	0.000258	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—stomach cancer	6.31e-05	0.000258	CcSEcCtD
Sirolimus—Dizziness—Capecitabine—stomach cancer	6.3e-05	0.000258	CcSEcCtD
Sirolimus—Vomiting—Docetaxel—stomach cancer	6.26e-05	0.000256	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—stomach cancer	6.25e-05	0.000255	CcSEcCtD
Sirolimus—Rash—Docetaxel—stomach cancer	6.21e-05	0.000254	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—stomach cancer	6.21e-05	0.000254	CcSEcCtD
Sirolimus—Dermatitis—Docetaxel—stomach cancer	6.2e-05	0.000253	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—stomach cancer	6.2e-05	0.000253	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—stomach cancer	6.17e-05	0.000252	CcSEcCtD
Sirolimus—Headache—Docetaxel—stomach cancer	6.17e-05	0.000252	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—stomach cancer	6.14e-05	0.000251	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—stomach cancer	6.14e-05	0.000251	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—stomach cancer	6.13e-05	0.00025	CcSEcCtD
Sirolimus—Infection—Doxorubicin—stomach cancer	6.1e-05	0.000249	CcSEcCtD
Sirolimus—Pain—Methotrexate—stomach cancer	6.07e-05	0.000248	CcSEcCtD
Sirolimus—Vomiting—Capecitabine—stomach cancer	6.06e-05	0.000248	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—stomach cancer	6.05e-05	0.000247	CcSEcCtD
Sirolimus—Shock—Doxorubicin—stomach cancer	6.05e-05	0.000247	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—stomach cancer	6.03e-05	0.000246	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—stomach cancer	6.02e-05	0.000246	CcSEcCtD
Sirolimus—Rash—Capecitabine—stomach cancer	6.01e-05	0.000246	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—stomach cancer	6.01e-05	0.000245	CcSEcCtD
Sirolimus—Dermatitis—Capecitabine—stomach cancer	6e-05	0.000245	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—stomach cancer	6e-05	0.000245	CcSEcCtD
Sirolimus—Headache—Capecitabine—stomach cancer	5.97e-05	0.000244	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—stomach cancer	5.97e-05	0.000244	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—stomach cancer	5.96e-05	0.000244	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—stomach cancer	5.94e-05	0.000243	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—stomach cancer	5.92e-05	0.000242	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—stomach cancer	5.9e-05	0.000241	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—stomach cancer	5.86e-05	0.000239	CcSEcCtD
Sirolimus—Nausea—Docetaxel—stomach cancer	5.85e-05	0.000239	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—stomach cancer	5.85e-05	0.000239	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—stomach cancer	5.85e-05	0.000239	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—stomach cancer	5.8e-05	0.000237	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—stomach cancer	5.77e-05	0.000236	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—stomach cancer	5.74e-05	0.000235	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—stomach cancer	5.73e-05	0.000234	CcSEcCtD
Sirolimus—Pain—Epirubicin—stomach cancer	5.68e-05	0.000232	CcSEcCtD
Sirolimus—Constipation—Epirubicin—stomach cancer	5.68e-05	0.000232	CcSEcCtD
Sirolimus—Nausea—Capecitabine—stomach cancer	5.66e-05	0.000231	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—stomach cancer	5.61e-05	0.000229	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—stomach cancer	5.61e-05	0.000229	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—stomach cancer	5.6e-05	0.000229	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—stomach cancer	5.56e-05	0.000227	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—stomach cancer	5.52e-05	0.000225	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—stomach cancer	5.48e-05	0.000224	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—stomach cancer	5.47e-05	0.000224	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—stomach cancer	5.46e-05	0.000223	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—stomach cancer	5.43e-05	0.000222	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—stomach cancer	5.41e-05	0.000221	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—stomach cancer	5.34e-05	0.000218	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—stomach cancer	5.3e-05	0.000217	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—stomach cancer	5.25e-05	0.000215	CcSEcCtD
Sirolimus—Pain—Doxorubicin—stomach cancer	5.25e-05	0.000215	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—stomach cancer	5.25e-05	0.000214	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—stomach cancer	5.25e-05	0.000214	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—stomach cancer	5.23e-05	0.000214	CcSEcCtD
Sirolimus—Asthenia—Methotrexate—stomach cancer	5.09e-05	0.000208	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—stomach cancer	5.06e-05	0.000207	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—stomach cancer	5.02e-05	0.000205	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—stomach cancer	5.02e-05	0.000205	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—stomach cancer	4.89e-05	0.0002	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—stomach cancer	4.86e-05	0.000198	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—stomach cancer	4.86e-05	0.000198	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—stomach cancer	4.86e-05	0.000198	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—stomach cancer	4.76e-05	0.000195	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—stomach cancer	4.7e-05	0.000192	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—stomach cancer	4.69e-05	0.000192	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—stomach cancer	4.54e-05	0.000186	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—stomach cancer	4.53e-05	0.000185	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—stomach cancer	4.51e-05	0.000184	CcSEcCtD
Sirolimus—Rash—Methotrexate—stomach cancer	4.47e-05	0.000183	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—stomach cancer	4.47e-05	0.000183	CcSEcCtD
Sirolimus—Headache—Methotrexate—stomach cancer	4.45e-05	0.000182	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—stomach cancer	4.41e-05	0.00018	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—stomach cancer	4.39e-05	0.000179	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—stomach cancer	4.35e-05	0.000178	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—stomach cancer	4.22e-05	0.000173	CcSEcCtD
Sirolimus—Nausea—Methotrexate—stomach cancer	4.22e-05	0.000172	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—stomach cancer	4.2e-05	0.000172	CcSEcCtD
Sirolimus—Rash—Epirubicin—stomach cancer	4.19e-05	0.000171	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—stomach cancer	4.18e-05	0.000171	CcSEcCtD
Sirolimus—Headache—Epirubicin—stomach cancer	4.16e-05	0.00017	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—stomach cancer	4.06e-05	0.000166	CcSEcCtD
Sirolimus—Nausea—Epirubicin—stomach cancer	3.94e-05	0.000161	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—stomach cancer	3.91e-05	0.00016	CcSEcCtD
Sirolimus—Rash—Doxorubicin—stomach cancer	3.87e-05	0.000158	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—stomach cancer	3.87e-05	0.000158	CcSEcCtD
Sirolimus—Headache—Doxorubicin—stomach cancer	3.85e-05	0.000157	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—stomach cancer	3.65e-05	0.000149	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—stomach cancer	7.75e-06	3.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—stomach cancer	7.7e-06	3.26e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK3—stomach cancer	7.7e-06	3.26e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MAPK1—stomach cancer	7.67e-06	3.25e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—stomach cancer	7.67e-06	3.25e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—HMOX1—stomach cancer	7.66e-06	3.24e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO1—stomach cancer	7.59e-06	3.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—stomach cancer	7.58e-06	3.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK8—stomach cancer	7.58e-06	3.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APC—stomach cancer	7.56e-06	3.2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALDOB—stomach cancer	7.56e-06	3.2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FBP1—stomach cancer	7.54e-06	3.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NDUFA2—stomach cancer	7.54e-06	3.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA1—stomach cancer	7.54e-06	3.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CKB—stomach cancer	7.54e-06	3.19e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—stomach cancer	7.49e-06	3.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6R—stomach cancer	7.44e-06	3.15e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FYN—stomach cancer	7.39e-06	3.13e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL8—stomach cancer	7.35e-06	3.11e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK1—stomach cancer	7.33e-06	3.1e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—stomach cancer	7.32e-06	3.1e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ERCC2—stomach cancer	7.31e-06	3.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—stomach cancer	7.28e-06	3.08e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—stomach cancer	7.26e-06	3.07e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—stomach cancer	7.25e-06	3.07e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TYMS—stomach cancer	7.22e-06	3.05e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1B—stomach cancer	7.18e-06	3.04e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1A—stomach cancer	7.17e-06	3.03e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTM1—stomach cancer	7.14e-06	3.02e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLIN2—stomach cancer	7.08e-06	3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALOX5—stomach cancer	7.02e-06	2.97e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6R—stomach cancer	7.02e-06	2.97e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—stomach cancer	7.02e-06	2.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SERPINE1—stomach cancer	6.97e-06	2.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—stomach cancer	6.96e-06	2.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGFR2—stomach cancer	6.94e-06	2.94e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—stomach cancer	6.93e-06	2.93e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—stomach cancer	6.92e-06	2.93e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DPYD—stomach cancer	6.91e-06	2.92e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA2—stomach cancer	6.89e-06	2.92e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MTHFR—stomach cancer	6.87e-06	2.91e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—stomach cancer	6.85e-06	2.9e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—JUN—stomach cancer	6.83e-06	2.89e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—APOA1—stomach cancer	6.76e-06	2.86e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—stomach cancer	6.74e-06	2.85e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CD44—stomach cancer	6.73e-06	2.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—RHOA—stomach cancer	6.72e-06	2.84e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PGAM1—stomach cancer	6.72e-06	2.84e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NT5E—stomach cancer	6.72e-06	2.84e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ERCC2—stomach cancer	6.71e-06	2.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—stomach cancer	6.69e-06	2.83e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—stomach cancer	6.66e-06	2.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOS3—stomach cancer	6.65e-06	2.82e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—stomach cancer	6.65e-06	2.81e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1A—stomach cancer	6.62e-06	2.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK3—stomach cancer	6.62e-06	2.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SERPINE1—stomach cancer	6.58e-06	2.78e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK8—stomach cancer	6.47e-06	2.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—stomach cancer	6.44e-06	2.73e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDH7A1—stomach cancer	6.41e-06	2.71e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PLCE1—stomach cancer	6.41e-06	2.71e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—stomach cancer	6.4e-06	2.71e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—stomach cancer	6.36e-06	2.69e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS2—stomach cancer	6.36e-06	2.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RHOA—stomach cancer	6.35e-06	2.68e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CAV1—stomach cancer	6.34e-06	2.68e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOA1—stomach cancer	6.32e-06	2.68e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—stomach cancer	6.31e-06	2.67e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK1—stomach cancer	6.3e-06	2.66e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—stomach cancer	6.3e-06	2.66e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOS3—stomach cancer	6.28e-06	2.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1B—stomach cancer	6.24e-06	2.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—stomach cancer	6.22e-06	2.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—stomach cancer	6.19e-06	2.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—stomach cancer	6.17e-06	2.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CAV1—stomach cancer	6.16e-06	2.61e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—stomach cancer	6.16e-06	2.61e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—stomach cancer	6.15e-06	2.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOA1—stomach cancer	6.15e-06	2.6e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UMPS—stomach cancer	6.14e-06	2.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—stomach cancer	6.13e-06	2.59e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK3—stomach cancer	6.11e-06	2.59e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTT1—stomach cancer	6.11e-06	2.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—stomach cancer	6.09e-06	2.57e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	6.06e-06	2.56e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2A6—stomach cancer	6.04e-06	2.56e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—stomach cancer	5.97e-06	2.53e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—stomach cancer	5.95e-06	2.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—stomach cancer	5.94e-06	2.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—stomach cancer	5.94e-06	2.51e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—stomach cancer	5.91e-06	2.5e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—stomach cancer	5.9e-06	2.49e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—stomach cancer	5.88e-06	2.49e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKR1C3—stomach cancer	5.88e-06	2.49e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—stomach cancer	5.87e-06	2.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PRKCB—stomach cancer	5.87e-06	2.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6ST—stomach cancer	5.84e-06	2.47e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CAV1—stomach cancer	5.82e-06	2.46e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK1—stomach cancer	5.82e-06	2.46e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—stomach cancer	5.81e-06	2.46e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOA1—stomach cancer	5.8e-06	2.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1B—stomach cancer	5.76e-06	2.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—stomach cancer	5.76e-06	2.44e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO1—stomach cancer	5.73e-06	2.42e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPP2R1A—stomach cancer	5.72e-06	2.42e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PDHA1—stomach cancer	5.71e-06	2.42e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ECHS1—stomach cancer	5.71e-06	2.42e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK3—stomach cancer	5.65e-06	2.39e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—stomach cancer	5.63e-06	2.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK8—stomach cancer	5.62e-06	2.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—stomach cancer	5.61e-06	2.37e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—stomach cancer	5.61e-06	2.37e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—stomach cancer	5.57e-06	2.36e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—stomach cancer	5.57e-06	2.36e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMOX1—stomach cancer	5.54e-06	2.34e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—stomach cancer	5.49e-06	2.32e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—stomach cancer	5.49e-06	2.32e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—stomach cancer	5.47e-06	2.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1B—stomach cancer	5.44e-06	2.3e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK1—stomach cancer	5.37e-06	2.27e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—stomach cancer	5.37e-06	2.27e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMP—stomach cancer	5.37e-06	2.27e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FADS1—stomach cancer	5.37e-06	2.27e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	5.36e-06	2.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—stomach cancer	5.32e-06	2.25e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—stomach cancer	5.22e-06	2.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6R—stomach cancer	5.21e-06	2.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—stomach cancer	5.19e-06	2.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—stomach cancer	5.18e-06	2.19e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—stomach cancer	5.16e-06	2.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—stomach cancer	5.14e-06	2.18e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—stomach cancer	5.11e-06	2.16e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CD44—stomach cancer	5.08e-06	2.15e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—stomach cancer	5.08e-06	2.15e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—stomach cancer	5.06e-06	2.14e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—stomach cancer	5.05e-06	2.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—stomach cancer	5.04e-06	2.13e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SREBF2—stomach cancer	5.03e-06	2.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—stomach cancer	5.02e-06	2.12e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—stomach cancer	5.01e-06	2.12e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RORA—stomach cancer	4.97e-06	2.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK3—stomach cancer	4.91e-06	2.08e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK8—stomach cancer	4.9e-06	2.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SERPINE1—stomach cancer	4.88e-06	2.06e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ERCC2—stomach cancer	4.85e-06	2.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—stomach cancer	4.84e-06	2.05e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—NOS3—stomach cancer	4.79e-06	2.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—stomach cancer	4.75e-06	2.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RHOA—stomach cancer	4.71e-06	1.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK1—stomach cancer	4.67e-06	1.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—stomach cancer	4.67e-06	1.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—stomach cancer	4.67e-06	1.97e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—stomach cancer	4.66e-06	1.97e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOS3—stomach cancer	4.66e-06	1.97e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDOB—stomach cancer	4.66e-06	1.97e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—stomach cancer	4.6e-06	1.95e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—stomach cancer	4.56e-06	1.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK3—stomach cancer	4.54e-06	1.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—stomach cancer	4.52e-06	1.91e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—stomach cancer	4.51e-06	1.91e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—stomach cancer	4.48e-06	1.89e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—stomach cancer	4.47e-06	1.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—stomach cancer	4.41e-06	1.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—stomach cancer	4.41e-06	1.87e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—NOS3—stomach cancer	4.4e-06	1.86e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—stomach cancer	4.38e-06	1.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—stomach cancer	4.36e-06	1.84e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALOX5—stomach cancer	4.33e-06	1.83e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPP2R1A—stomach cancer	4.32e-06	1.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK1—stomach cancer	4.32e-06	1.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—stomach cancer	4.31e-06	1.83e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—stomach cancer	4.31e-06	1.82e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK3—stomach cancer	4.28e-06	1.81e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DPYD—stomach cancer	4.26e-06	1.8e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—stomach cancer	4.24e-06	1.79e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CAV1—stomach cancer	4.21e-06	1.78e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOA1—stomach cancer	4.2e-06	1.77e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMOX1—stomach cancer	4.18e-06	1.77e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—stomach cancer	4.16e-06	1.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—stomach cancer	4.13e-06	1.75e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—stomach cancer	4.13e-06	1.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—stomach cancer	4.08e-06	1.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK1—stomach cancer	4.07e-06	1.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—stomach cancer	4.07e-06	1.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—stomach cancer	4.06e-06	1.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1B—stomach cancer	4.04e-06	1.71e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—stomach cancer	4.02e-06	1.7e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—stomach cancer	3.94e-06	1.67e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—stomach cancer	3.89e-06	1.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—stomach cancer	3.85e-06	1.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—stomach cancer	3.85e-06	1.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—stomach cancer	3.84e-06	1.63e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTT1—stomach cancer	3.77e-06	1.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—stomach cancer	3.75e-06	1.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—stomach cancer	3.74e-06	1.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—stomach cancer	3.74e-06	1.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—stomach cancer	3.73e-06	1.58e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2A6—stomach cancer	3.72e-06	1.57e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—stomach cancer	3.7e-06	1.56e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ERCC2—stomach cancer	3.66e-06	1.55e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK8—stomach cancer	3.64e-06	1.54e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKR1C3—stomach cancer	3.62e-06	1.53e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—stomach cancer	3.59e-06	1.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—stomach cancer	3.53e-06	1.49e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO1—stomach cancer	3.53e-06	1.49e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—stomach cancer	3.46e-06	1.47e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—stomach cancer	3.44e-06	1.46e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—stomach cancer	3.42e-06	1.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—stomach cancer	3.36e-06	1.42e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—stomach cancer	3.32e-06	1.41e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—stomach cancer	3.32e-06	1.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—stomach cancer	3.32e-06	1.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—stomach cancer	3.27e-06	1.38e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—NOS3—stomach cancer	3.18e-06	1.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK3—stomach cancer	3.18e-06	1.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CAV1—stomach cancer	3.17e-06	1.34e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOA1—stomach cancer	3.17e-06	1.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—stomach cancer	3.13e-06	1.32e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CD44—stomach cancer	3.13e-06	1.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—stomach cancer	3.09e-06	1.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK1—stomach cancer	3.02e-06	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—stomach cancer	3.02e-06	1.28e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—stomach cancer	2.91e-06	1.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—stomach cancer	2.85e-06	1.21e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—stomach cancer	2.79e-06	1.18e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—stomach cancer	2.7e-06	1.14e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPP2R1A—stomach cancer	2.66e-06	1.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—stomach cancer	2.62e-06	1.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—stomach cancer	2.61e-06	1.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMOX1—stomach cancer	2.57e-06	1.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—stomach cancer	2.54e-06	1.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—stomach cancer	2.51e-06	1.06e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—stomach cancer	2.48e-06	1.05e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—stomach cancer	2.43e-06	1.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—stomach cancer	2.43e-06	1.03e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NOS3—stomach cancer	2.4e-06	1.01e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—stomach cancer	2.4e-06	1.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—stomach cancer	2.32e-06	9.82e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ERCC2—stomach cancer	2.25e-06	9.54e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—stomach cancer	2.19e-06	9.28e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—stomach cancer	2.12e-06	8.97e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CAV1—stomach cancer	1.95e-06	8.27e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOA1—stomach cancer	1.95e-06	8.25e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—stomach cancer	1.79e-06	7.57e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—stomach cancer	1.72e-06	7.27e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—stomach cancer	1.55e-06	6.54e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NOS3—stomach cancer	1.48e-06	6.25e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—stomach cancer	1.35e-06	5.72e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—stomach cancer	1.35e-06	5.71e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—stomach cancer	8.32e-07	3.52e-06	CbGpPWpGaD
